Micromet Inc (MITI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI)

MITI 0.0955

-6.4%

3:02 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Arthur Radley	6/13/2011 9:45:58 AM
	Read Replies (1) of 196

Needham & Company Maintains a 'Buy' on Micromet (MITI); Data Strongly Support Pivotal Testing in 2012 8:09 am ET 06/13/2011 - StreetInsider Needham & Company maintains a 'Buy' on Micromet (NASDAQ: MITI), PT $13. Needham analyst says, "We are positively inclined towards the blinatumomab development plan. We note little competition in this space after a review of the ASCO and EHA Meeting presentations in adult r/r ALL. We note multiple data presentations as potential stock catalysts, including updated data from a Phase 1 trial in r/r NHL (ICML, Lugano, June 16), initiation of a Phase ½ trial of blinatumomab in pediatric ALL (mid-2011), and final data from the Phase 2 trial described above (ASH Meeting, December 10-13, 2011)." For more ratings news on Micromet click here and for the rating history of Micromet click here. Shares of Micromet closed at $5.75 yesterday, with a 52 week range of $4.75-$8.63. Needham & Company Maintains a 'Buy' on Micromet (MITI); Data Strongly ... StreetInsider - 8:09 AM ET.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next